Cross-cultural treatment preferences: a call for diversity in drug development.

IF 2.2 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Dana M Dijkgraaf, Pantea Kiani, Maureen N Zijlstra, Joris C Verster
{"title":"Cross-cultural treatment preferences: a call for diversity in drug development.","authors":"Dana M Dijkgraaf, Pantea Kiani, Maureen N Zijlstra, Joris C Verster","doi":"10.1080/03007995.2025.2537298","DOIUrl":null,"url":null,"abstract":"<p><p>Patient preferences for treatment characteristics-such as dosage form, taste, smell, and ingredients-play a key role in adherence, yet these preferences differ widely across cultures and are frequently overlooked in pharmaceutical development. Prescription medicines must meet strict safety and effectiveness standards, restricting flexibility, whereas over-the-counter supplements allow more freedom, though often without proven benefits. Developing diverse formulations is expensive and time-consuming, and patients need clear guidance to make informed choices without feeling overwhelmed or questioning their doctors. This tension highlights a disconnect between patient desires, scientific validation, and practical feasibility. We urge healthcare providers, pharmaceutical companies, and patients to engage in dialogue to discuss patient preferences and diversity in drug development. By creating treatments that reflect cultural needs and improving patient education, adherence and equity in healthcare can improve, provided the scientific, economic, and logistical hurdles are addressed effectively.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-5"},"PeriodicalIF":2.2000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Research and Opinion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03007995.2025.2537298","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Patient preferences for treatment characteristics-such as dosage form, taste, smell, and ingredients-play a key role in adherence, yet these preferences differ widely across cultures and are frequently overlooked in pharmaceutical development. Prescription medicines must meet strict safety and effectiveness standards, restricting flexibility, whereas over-the-counter supplements allow more freedom, though often without proven benefits. Developing diverse formulations is expensive and time-consuming, and patients need clear guidance to make informed choices without feeling overwhelmed or questioning their doctors. This tension highlights a disconnect between patient desires, scientific validation, and practical feasibility. We urge healthcare providers, pharmaceutical companies, and patients to engage in dialogue to discuss patient preferences and diversity in drug development. By creating treatments that reflect cultural needs and improving patient education, adherence and equity in healthcare can improve, provided the scientific, economic, and logistical hurdles are addressed effectively.

跨文化治疗偏好:对药物开发多样性的呼吁。
患者对治疗特征的偏好——如剂型、味道、气味和成分——在依从性中起着关键作用,然而这些偏好在不同文化中差异很大,在药物开发中经常被忽视。处方药必须符合严格的安全性和有效性标准,限制了灵活性,而非处方补充剂允许更多的自由,尽管通常没有证明的好处。开发不同的配方既昂贵又耗时,患者需要明确的指导才能做出明智的选择,而不会感到不知所措或质疑他们的医生。这种紧张关系凸显了患者愿望、科学验证和实际可行性之间的脱节。我们敦促医疗保健提供者、制药公司和患者进行对话,讨论患者的偏好和药物开发的多样性。通过创建反映文化需求的治疗方法并改善患者教育,只要有效地解决科学、经济和后勤障碍,就可以改善医疗保健中的依从性和公平性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Medical Research and Opinion
Current Medical Research and Opinion 医学-医学:内科
CiteScore
4.40
自引率
4.30%
发文量
247
审稿时长
3-8 weeks
期刊介绍: Current Medical Research and Opinion is a MEDLINE-indexed, peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, Phase II-IV studies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged. Preclinical, Phase I, pharmacoeconomic, outcomes and quality of life studies may also be considered if there is clear clinical relevance
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信